MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre analyze to evaluate several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Principal demo targets had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis individuals, even though one of many https://garrisonl666whu8.wikifrontier.com/user